Combinati believes simplicity shouldn’t require sacrificing robustness, quality or rigor – in fact, it should enable it. Our easy-to-use digital PCR platform offers absolute quantification to track disease-relevant biomarkers over time with high accuracy and precision. Comprised of a single instrument and a single consumable, the core microfluidic technology enables partitioning of samples with minimal waste. Combined with the ability to robustly reject false positives and easily adapt traditional qPCR assays, Combinati aims to democratize digital PCR for researchers all over the world.
Top: Steve Gallagher (Software), Robert Lin (Customer Success), Andrew Zayac (Engineering), Lingxia Jiang (Assay)
(Middle) Adam Langston (BD/Sales), Alan Barber (Software), Hien Nguyen (Application), Jim Kenemuth (Software)
Bottom: Paul Hung (CEO), Christina Bouwens (Application), Cesar Hernandez (Software), Felicia Linn (Consumable)